久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

BeiGene protects the world with affordable Chinese therapies

By Liu Zhihua | China Daily | Updated: 2019-12-30 10:38
Share
Share - WeChat
Wu Xiaobin, president of BeiGene. [Photo provided to China Daily]

The two drugs were approved only six months later as two foreign anti-PD-1 treatments entered the China market, and followed shortly by a third domestic PD-1 treatment early this year.

BeiGene's anti-PD-1 treatment also obtained approval from the Chinese drug regulatory authorities on Saturday.

The company has been also implementing about 20 clinical trial programs globally on Brukinsa's efficacy on other types of blood or lymph tumors, with high hope to get more market approvals in the near future.

The company, which has nearly 10 new drug candidates in pipeline, is a partner in a global strategic oncology collaboration with Amgen, a California-based biopharmaceutical company that is a global leader in this niche.

Chinese biotech firms are increasingly offering China-developed high-quality treatments to Chinese patients, which will help challenge the expensive prices of imported drugs, Wu said.

With innovative drugs such as anti-PD-1 and Brukinsa, Chinese drug companies also have the ability to offer treatment options for patients abroad, especially those in the Belt and Road economies, he said.

Wu joined the Beijing-headquartered company in 2018 from Pfizer China, which he headed since 2009.

His jump to the Chinese biotech startup founded in 2010 surprised many as he had more than 26 years of rich experience in the pharmaceutical industry, including 17 years leading China operations of big-name multinational pharmaceuticals such as Wyeth and Bayer.

He returned to Beijing in 1996 to co-build Bayer's China branch as marketing head. Prior, he was in Germany where he received a master's degree in molecular biology and a PhD in biochemistry and pharmacology from the University of Konstanz. He started his career at Bayer's sales and marketing in 1992.

In 2004, he rose to general manager of Wyeth China. In 2009, as Pfizer acquired Wyeth, he was named head of the combined group.

He also served as vice chairman of the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment since 2008.

Under his belt are numerous industry awards, including the "Person of the Year" in Healthy China Awards 2017, "2017 Top 10 Most Influential Persons in the Chinese Healthcare Industry" and the "2017 Social Responsibility Eminent Person Award".

|<< Previous 1 2   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产精品夜色视频一区二区 | 女人把腿劈开让男人桶的网站 | 亚洲高清免费观看 | 精品久久久久久影院免费 | 久久久国产亚洲精品 | 亚洲乱强 | 国产午夜爽爽窝窝在线观看 | 久久国内精品 | 亚洲精品国产一区二区三 | 日韩欧美久久一区二区 | 91精品全国免费观看 | 99国产精品免费视频观看 | 免费人成在线观看播放国产 | 国产精品久久久久久久久久直 | 亚洲综合91 | 男女性高爱潮免费网站 | 黄色美女网站在线观看 | 黄网国产 | 伊人365影院 | 青青爽国产手机在线观看免费 | 国产精品亲子乱子伦xxxx裸 | 国产精品一二区 | 91精品欧美一区二区三区 | 一区二区高清在线 | 久久一区二区三区免费播放 | 手机看片久久高清国产日韩 | 69凹凸国产成人精品视频 | 精品一区二区三区在线观看l | 美女视频黄色在线观看 | 国产欧美日韩综合二区三区 | 欧美久久视频 | 色偷偷女男人的天堂亚洲网 | 99国产在线播放 | 新体操真 | 偷偷操不一样的久久 | 久久高清影院 | 国产在线播放成人免费 | 日韩在线中文字幕 | 国产午夜精品理论片小yo奈 | 九九成人免费视频 | 2021一本久道 |